{
    "doi": "https://doi.org/10.1182/blood.V106.11.5040.5040",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=326",
    "start_url_page_num": 326,
    "is_scraped": "1",
    "article_title": "MDM2 Antagonists Activate p53 and Synergize with Genotoxic Drugs To Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells but Not in T Cells. ",
    "article_date": "November 16, 2005",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of long-lived CD5+ B lymphocytes. Several drugs used currently in the therapy of B-CLL act, at least partially, through activation of the p53 pathway. Recently, non-genotoxic small-molecule activators of p53, the nutlins, have been identified that inhibit p53-MDM2 binding. We have investigated the antitumor potential of nutlin-3 in B-CLL and find that it can effectively activate the p53 pathway and induce apoptosis in cells with wild-type but not mutant p53. The half-maximal effective concentration (EC50) for B-CLL cells was 4.7 \u00b1 1.5 \u03bcM (n = 8). Nutlin-3 stabilized p53 and induced several p53 target genes including MDM2, p21, PUMA, Bax, PIG3 and WIG1. At lower concentrations, nutlin-3 synergized with the genotoxic drugs doxorubicin, chlorambucil, and fludarabine but not with acadesine, that induces p53-independent apoptosis. Normal human T cells showed lower sensitivity to nutlin-3 than B-CLL cells and no synergism with the genotoxic drugs. These results suggest that MDM2 antagonists alone or in combination with chemotherapeutic drugs may offer a new treatment option for B-CLL.",
    "topics": [
        "antagonists",
        "apoptosis",
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "t-lymphocytes",
        "acadesine",
        "antineoplastic agents",
        "chlorambucil",
        "doxorubicin",
        "fludarabine"
    ],
    "author_names": [
        "Joan Gil, PhD",
        "Llorenc\u0327 Coll-Mulet, BD",
        "Daniel Iglesias-Serret, PhD",
        "Antonio F. Santidria\u0301n, BD",
        "Esther Castan\u0303o, PhD",
        "Clara Campa\u0300s, PhD",
        "Montserrat Barraga\u0301n, PhD",
        "Ana M. Cosialls, BD",
        "Merce\u0301 De Frias, BD",
        "Alberto Ferna\u0301ndez de Sevilla, MD, PhD",
        "Alicia Domingo, MD",
        "Lyubomir T. Vassilev, PhD",
        "Gabriel Pons, MD, PhD"
    ],
    "author_affiliations": [
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Dept. Hematologia Cli\u0301nica, IDIBELL-Institut Catala d\u2019Oncologia, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Servei d\u2019Hematologia, IDIBELL-Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ],
        [
            "Discovery Oncology, Roche Research Center, Hoffmann-La Roche, Inc, Nutley, NJ, USA"
        ],
        [
            "Dept. Cie\u0300ncies Fisiolo\u0300giques II, IDIBELL-Universitat de Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"
        ]
    ],
    "first_author_latitude": "41.3867751",
    "first_author_longitude": "2.1637277999999998"
}